ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
COVID vaccines

Samsung Biologics to make Moderna vaccine in Biden summit takeaway

Incheon production deal comes after Moon government faced criticism on supply front

Samsung Biologics will produce hundreds of millions of Moderna vaccines starting this summer. (Photo courtesy of Samsung Biologics)

SEOUL -- South Korean drugmaker Samsung Biologics will begin producing the Moderna coronavirus vaccine following an agreement struck during President Moon Jae-in's trip to Washington last week.

The company will produce hundreds of millions of vaccine doses at its facilities in Incheon and plans to ship the drug domestically and to other destinations excluding the U.S., according to Sunday's announcement.

This will mark the first vaccine production deal for Samsung Biologics, one of the world's leading contract manufacturers of biopharmaceuticals. The production arrangement could speed up South Korea's vaccine rollout.

Samsung Biologics and Moderna signed the agreement Saturday at an event bringing together American and South Korean vaccine companies, a day after Moon's summit with U.S. President Joe Biden.

The South Korean government already had a deal with Moderna to purchase 40 million doses of the vaccine.

The Moon administration's coronavirus response has faced criticism for its initial focus on prevention, which detractors say led to delays in securing vaccine supplies despite the country's strength in pharmaceutical manufacturing. Besides Samsung Biologics, South Korea is home to SK Bioscience.

The Moderna deal gives Moon's government a win on the vaccine front and an opportunity for the country to gain more production expertise.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Try 1 month for $0.99

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends July 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to Nikkei Asia has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more